{"groups":[{"description":"Chemotherapy alone until disease progression, unacceptable toxicity, or patient refusal\n\nChemotherapy: As prescribed","id":"FG000","title":"Chemotherapy"},{"description":"Chemotherapy and Bevacizumab until disease progression, unacceptable toxicity, or patient refusal\n\nChemotherapy: As prescribed\n\nBevacizumab: Bevacizumab, 5 mg/kg intravenously (IV) on days 1 and 14 of each 4 week cycle, or 7.5 mg/kg IV on days 1 and 22 of each 6 week cycle.","id":"FG001","title":"Chemotherapy + Bevacizumab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"394"},{"groupId":"FG001","numSubjects":"385"}],"type":"Died"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"10"}],"type":"Lost to Follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"411"},{"groupId":"FG001","numSubjects":"409"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"410"},{"groupId":"FG001","numSubjects":"409"}],"type":"Intention to Treat"},{"achievements":[{"groupId":"FG000","numSubjects":"407"},{"groupId":"FG001","numSubjects":"403"}],"type":"Received at Least One Dose"},{"achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"14"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"402"},{"groupId":"FG001","numSubjects":"395"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"This study enrolled 820 patients at 220 sites located in 15 countries in Europe and Saudi Arabia. Study AIO KRK 0504 enrolled 261 patients, and 559 patients subsequently enrolled in Study ML18147 when the study was transferred to Hoffmann LaRoche (in 2008)."}